Cite
MLA Citation
Mark Sulkowski et al.. “Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.” Lancet, vol. 385, no. 9973, 2015, pp. 1087–1097. http://access.bl.uk/ark:/81055/vdc_100042385058.0x000046